Carlos Arteaga I FGFR Pathway as a Mechanism of Resistance to Endocrine Therapy in Breast Cancer

• Speaker: Carlos Arteaga, Professor of Internal Medicine; Director, Simmons Comprehensive Cancer Center; and Associate Dean for Oncology Programs
• Talk title: FGFR Pathway as a Mechanism of Resistance to Endocrine Therapy in Breast Cancer
• Host: Josep Tabernero
• Date & time: Monday 16th May, at 12:00 CET

Carlos Arteaga serves as the Director and Principal Investigator of the NCI-designated Simmons Comprehensive Cancer Center (SCCC) Support Grant P30 CA142543, and Associate Dean of Oncology Programs at UT Southwestern. In this role, he oversee cancer-related activities and resources at UTSW, including administrative and laboratory space assigned to the Center, cancer clinical services, membership, resource allocations, cancer research strategic planning, cancer education and training, and mentoring across the research continuum. Resources in the SCCC are relevant in that they will provide support to the research aims proposed herein. His laboratory focuses on translational research in breast cancer with a focus of mechanisms of action and resistance of antiestrogens and targeted therapies and investigator-initiated clinical trials. In this area, his group has reported several mechanisms of drug resistance to antiestrogens and CDK4/6 inhibitors, such as activating mutations in HER2 (ERBB2) and the PI3K pathway and FGFR1 amplification, in many cases derived from molecular information generated in primary tumor specimens. Several of his prior trainees hold independent positions and/or leadership roles in academic institutions.

Registration